Market Outlook

By 2035, the U.S. Benchtop Point-of-Care Testing Devices Market is expected to reach approximately USD 6.22 billion, expanding at a CAGR of 9.20% during the forecast period 2026–2035. The market is estimated at USD 2.58 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

For the purpose of this report, benchtop point-of-care testing devices comprise compact or desktop diagnostic analyzer platforms designed to generate actionable results at or near the patient-care location, together with dedicated cartridges, cassettes, reagent packs, and platform-specific consumables that generate recurring revenue. The market includes molecular diagnostic analyzers, immunoassay systems, blood gas and electrolyte analyzers, HbA1c and cardiometabolic analyzers, compact hematology systems, coagulation platforms, and selected urinalysis and clinical chemistry systems. Standalone handheld glucose meters, continuous glucose monitoring systems, home self-testing kits without an analyzer, and high-throughput central laboratory systems are excluded.

The market is estimated to have expanded from approximately USD 2.05 billion in 2021 to USD 2.36 billion in 2024, before reaching USD 2.58 billion in 2025. Growth during the historical period reflected normalization after pandemic-driven respiratory testing demand, broader utilization of rapid molecular diagnostics, increasing adoption of instrumented immunoassay systems, continued decentralization of HbA1c and renal screening, and hospital investment in near-patient blood gas and critical-care testing. Under the forecast model, the market is expected to approach USD 2.82 billion in 2026, approximately USD 4.01 billion by 2030, and USD 6.22 billion by 2035.

The commercial attractiveness of this market is driven by a different economic model from conventional laboratory automation. Benchtop POCT systems typically create an installed-base relationship in which the analyzer establishes the workflow and the consumable generates repeat revenue. Manufacturers therefore compete on menu breadth, assay utilization, turnaround time, CLIA complexity, connectivity, cartridge economics, quality-control automation, uptime, service responsiveness, and the ability to place systems across multiple decentralized sites under enterprise contracts.

Demand is supported by the scale of U.S. chronic and acute disease. More than 40 million Americans are estimated to have diabetes, while over 115 million adults have prediabetes. Approximately 37 million adults are estimated to have chronic kidney disease. Respiratory disease also creates substantial seasonal testing demand; a recent U.S. influenza season generated tens of millions of illnesses and hundreds of thousands of hospitalizations. These disease pools create sustained opportunities for HbA1c, albumin-to-creatinine ratio, respiratory molecular testing, blood gas testing, electrolytes, coagulation, infectious disease diagnostics, and other near-patient assays.

The U.S. healthcare infrastructure further supports decentralized testing. More than 6,000 hospitals, approximately 907,000 staffed hospital beds, thousands of physician practices, emergency departments, urgent care centers, ambulatory facilities, retail clinics, community health centers, specialty practices, and decentralized hospital laboratories create a highly fragmented but commercially attractive installed-base opportunity.

 

Introduction

According to the U.S. Benchtop Point-of-Care Testing Devices Market Report, the competitive importance of benchtop POCT comes from its position between handheld rapid testing and centralized laboratory automation. These systems offer greater analytical capability and automation than basic lateral-flow or handheld devices while requiring less infrastructure, staffing, batch volume, and physical space than conventional laboratory analyzers.

The clinical value proposition is time compression. A test that would otherwise require specimen accessioning, transportation, laboratory queueing, batch processing, result validation, and transmission can often be moved directly into the patient encounter. In emergency medicine, critical care, infectious disease, diabetes management, urgent care, obstetrics, surgery, nephrology, and primary care, the value of POCT therefore extends beyond the laboratory cost of the assay. The economically relevant outcome can include faster therapeutic decisions, reduced waiting time, more rapid isolation decisions, shorter emergency department disposition cycles, same-visit treatment, improved compliance, lower loss to follow-up, and better use of clinical staff.

The category includes highly differentiated workflows. Compact molecular analyzers can produce PCR-quality respiratory or infectious disease results during a single visit. HbA1c systems allow diabetes practices to discuss therapeutic changes while the patient is still present. Blood gas analyzers can return acid-base, oxygenation, electrolyte, metabolite, and co-oximetry information within minutes in critical-care settings. Fluorescent immunoassay platforms provide objective instrument-read infectious disease results. Compact hematology systems can decentralize complete blood count testing where central-lab turnaround is operationally inefficient.

U.S. procurement behavior is increasingly enterprise-driven. Large integrated delivery networks may standardize platforms across hospitals, urgent care locations, physician offices, emergency departments, clinics, and satellite sites. As a result, manufacturers are increasingly required to demonstrate not simply analytical performance but system-wide economic value. Connectivity to LIS, HIS, middleware, electronic medical records, operator-management systems, and quality-control dashboards can influence purchasing decisions as much as analyzer specifications.

CLIA status is particularly important. A system that can operate under a Certificate of Waiver potentially addresses a much larger decentralized customer base than a platform requiring moderate-complexity laboratory infrastructure. Recent regulatory activity demonstrates continued expansion of CLIA-waived molecular, HbA1c, respiratory, infectious disease, and other instrumented testing categories.

From 2026 through 2035, competitive advantage will increasingly shift toward companies capable of combining rapid testing, multiplexing, automation, connected quality management, cybersecurity, data interoperability, simplified sample handling, and a broad assay pipeline on a common installed platform.

 

Key Market Drivers: What’s Fueling the U.S. Benchtop Point-of-Care Testing Devices Market Boom?

The first major driver is the continued decentralization of diagnostic decision-making. U.S. health systems increasingly operate across hospitals, physician offices, freestanding emergency departments, urgent care centers, ambulatory sites, infusion centers, retail clinics, and other outpatient facilities. Sending every specimen to a central laboratory can create turnaround-time penalties that undermine the economics of these distributed care models. Benchtop POCT provides a middle path between basic handheld testing and full laboratory automation.

The second driver is the chronic disease burden. More than 40 million Americans are estimated to have diabetes and more than 115 million adults have prediabetes. This creates an exceptionally large recurring testing pool for HbA1c. Kidney disease screening creates another important use case because diabetes and hypertension are major risk factors for CKD, and albumin-to-creatinine ratio testing can support earlier identification of renal damage. Benchtop platforms capable of combining HbA1c, urine albumin, creatinine, or related cardiometabolic parameters can therefore increase their economic value per installed site.

The third driver is infectious disease testing. Respiratory infections generate highly seasonal but very large testing volumes across urgent care, emergency departments, pediatric practices, physician offices, and hospital outpatient settings. The 2023–2024 U.S. influenza season alone was estimated to have caused around 40 million illnesses, 18 million medical visits, and approximately 470,000 hospitalizations. Rapid molecular analyzers capable of identifying influenza, RSV, SARS-CoV-2, Group A Streptococcus, and other respiratory pathogens are well positioned because the result can immediately alter antiviral use, antibiotic prescribing, isolation, referral, and patient disposition.

Sexually transmitted infections represent another expanding near-patient molecular opportunity. More than 2.4 million reported cases of chlamydia, gonorrhea, and syphilis were recorded nationally in 2023. Same-visit molecular testing can be especially valuable because traditional send-out workflows create risk that patients will not return for treatment. Expansion of benchtop molecular menus into chlamydia, gonorrhea, Mycoplasma genitalium, hepatitis C, and other infections materially increases the addressable assay volume per analyzer.

The fourth driver is emergency and critical-care workflow economics. Blood gases, electrolytes, lactate, glucose, creatinine, ionized calcium, co-oximetry, and related parameters frequently influence immediate decisions. Modern benchtop blood gas systems can return complex panels in roughly one to two minutes. The economic question is therefore not whether a centralized laboratory can technically perform the test, but whether the clinical team can afford the delay associated with transport and laboratory processing.

The fifth driver is the growth of CLIA-waived instrumented testing. FDA clearance combined with CLIA waiver materially lowers the operational barrier to decentralized deployment. The continuing addition of waived assays for platforms in respiratory testing, HbA1c, coagulation, molecular infectious disease, and other areas expands the revenue potential of the installed analyzer base.

The sixth driver is labor scarcity. Medical laboratory staffing constraints make it difficult for hospitals to solve every turnaround-time problem by adding central-laboratory personnel. POCT can redistribute selected testing into clinical workflows while retaining oversight through operator lockout, barcode identification, automatic quality control, connectivity, and centralized POCT management software. The strongest systems therefore do not eliminate laboratory governance; they make decentralized testing governable at scale.

The seventh driver is the commercial preference for recurring-consumable models. Once a benchtop analyzer is installed, validated, interfaced, included in staff training, and incorporated into clinical protocols, switching creates operational friction. Manufacturers with broad assay menus can increase cartridge utilization without repeatedly winning a new capital placement, producing attractive lifetime economics.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. benchtop POCT market is shifting from single-analyte speed toward platform productivity. Buyers increasingly want a small-footprint analyzer capable of supporting multiple clinical pathways rather than a collection of unrelated instruments.

Rapid molecular diagnostics is one of the most strategically important innovation areas. Compact PCR and cartridge-based nucleic acid amplification platforms are increasingly bringing central-laboratory-quality molecular workflows closer to the patient. FDA-cleared rapid molecular influenza tests can generate results in approximately 15–30 minutes on some platforms, while broader cartridges may require longer but still enable same-visit clinical decisions.

Multiplexing is becoming increasingly important. In respiratory disease, the clinical presentation of influenza, RSV, SARS-CoV-2, and other pathogens can overlap significantly. A multiplex result reduces sequential testing and provides physicians with more clinically actionable differentiation. Similar logic is moving into sexually transmitted infection testing and other syndromic applications.

Cartridge integration is another major competitive battleground. Modern platforms increasingly package sample processing, reagents, calibration information, internal controls, and waste containment into self-contained consumables. This reduces manual pipetting, training requirements, contamination risk, and operator variability. Systems that translate complex laboratory chemistry into a small number of operator steps are better suited for decentralized deployment.

Connectivity is becoming a fundamental procurement requirement. Benchtop POCT fleets may consist of dozens or hundreds of analyzers distributed across a health system. Buyers therefore need automated patient identification, operator certification, quality-control tracking, reagent lot management, result transmission, cybersecurity controls, remote troubleshooting, and enterprise dashboards. A low-cost analyzer with poor connectivity can become expensive when deployed at scale.

Automation of quality assurance is also differentiating blood gas and critical-care analyzers. Leading platforms increasingly monitor analytical performance continuously, automate calibration, detect potential errors, and document corrective actions. This reduces the burden on POCT coordinators and supports standardized testing outside the core laboratory.

Sample minimization is another innovation priority. Neonatal, pediatric, intensive-care, oncology, dialysis, and medically fragile patients benefit when analyzers require less blood. Small-volume testing also simplifies capillary collection and reduces cumulative phlebotomy burden in repeatedly tested patients.

The next innovation cycle will increasingly integrate diagnostic output with clinical decision support. Analyzer companies are moving toward systems in which the result is not an isolated number but part of an interoperable workflow linked to EHR documentation, antimicrobial stewardship, diabetes management, renal screening, patient triage, and quality reporting.

 

Segmentation Insights

The U.S. Benchtop Point-of-Care Testing Devices Market is segmented on the basis of product category, application, technology, sample type, and end user.

 

By Product Category

• Molecular diagnostic analyzers represent one of the fastest-growing and highest-strategic-value categories. This segment includes compact PCR and other nucleic acid amplification systems designed for respiratory infections, sexually transmitted infections, hepatitis, gastrointestinal pathogens, and other rapid molecular applications. Platforms such as cobas Liat, GeneXpert Xpress, ID NOW, BIOFIRE SPOTFIRE, and related systems illustrate the movement of molecular testing from specialized laboratories into urgent care, emergency care, clinics, and decentralized hospital sites. Revenue growth is supported by both analyzer placements and high-value recurring cartridges.
• Blood gas, electrolyte, and critical-care analyzers form a mature but economically resilient segment. These platforms measure combinations of pH, pCO2, pO2, electrolytes, glucose, lactate, hematocrit, co-oximetry, creatinine, and other critical parameters. Demand is concentrated in emergency departments, intensive-care units, operating rooms, respiratory care, neonatal care, cardiac programs, and trauma centers. Hospitals prioritize uptime, rapid turnaround, small sample volume, automated QC, and integration with centralized POCT management.
• HbA1c and cardiometabolic analyzers benefit from the enormous U.S. diabetes and prediabetes population. This category includes systems for HbA1c, albumin, creatinine, albumin-to-creatinine ratio, lipid profiles, and related metabolic testing. The commercial appeal comes from recurring chronic disease testing and the ability to make management decisions during the same clinical encounter.
• Instrumented immunoassay analyzers support influenza, RSV, SARS-CoV-2, Group A Streptococcus, Lyme disease, cardiac markers, pregnancy-related testing, and other targets. Objective optical interpretation reduces the subjectivity associated with visually read rapid tests. These analyzers are particularly relevant in high-throughput urgent care and physician-office environments.
• Compact hematology, coagulation, urinalysis, and clinical chemistry analyzers represent a diversified growth category. Benchtop CBC systems, coagulation analyzers, urine analyzers, and small chemistry systems allow physician offices, specialty practices, ambulatory centers, and satellite facilities to retain testing that might otherwise be sent to an external laboratory.

 

By Application

• Infectious disease testing is expected to represent the largest application opportunity. Respiratory infections generate substantial seasonal volume, while STI, hepatitis, and other molecular assays increase year-round utilization. The ability to connect diagnosis with treatment in one encounter is particularly valuable in urgent care, emergency departments, community health centers, sexual health clinics, and settings where follow-up is uncertain.
• Diabetes and renal disease management provide stable recurring demand. HbA1c testing supports long-term glycemic management, while urine albumin and creatinine testing can identify kidney damage. With more than 40 million Americans estimated to have diabetes and an even larger prediabetes population, the potential testing base is structurally large.
• Critical-care and emergency diagnostics represent a high-frequency application driven by clinical urgency. Blood gas, electrolyte, lactate, glucose, creatinine, and other analytes are important in sepsis, respiratory failure, trauma, shock, surgery, diabetic emergencies, and intensive care. Fast turnaround can influence ventilation management, fluid resuscitation, electrolyte replacement, and escalation of care.
• Cardiac and coagulation testing includes troponin and other cardiac markers, coagulation parameters, and assays supporting acute cardiovascular and anticoagulation decisions. Competition is influenced by analytical sensitivity, turnaround time, clinical guidelines, reimbursement, and whether the test can be integrated into emergency-department protocols.
• General primary-care and specialty diagnostics include hematology, urinalysis, pregnancy-related testing, selected chemistry, autoimmune and inflammation markers, gastrointestinal testing, and other decentralized applications. Growth will depend on whether an analyzer can economically consolidate several tests that a practice currently sends to a reference laboratory.

 

By Technology

• Nucleic acid amplification technologies are projected to record the strongest value growth. PCR and other molecular methods command premium assay pricing because they combine rapid turnaround with high analytical sensitivity and specificity. Cartridge simplification and CLIA waiver are broadening adoption outside molecular laboratories.
• Fluorescent and optical immunoassay technologies remain important in high-volume rapid testing. Instrument reading improves consistency compared with purely visual interpretation and creates opportunities for connectivity, automated result capture, and quality management.
• Electrochemical and biosensor-based technologies dominate blood gas, electrolyte, metabolite, and selected chemistry applications. Innovation is focused on miniaturized sensor architecture, cartridge stability, reduced calibration burden, small blood volumes, and real-time QC.
• Clinical chemistry and affinity-based technologies support HbA1c, albumin, creatinine, lipids, and other metabolic assays. These platforms compete on precision, laboratory correlation, time to result, cartridge simplicity, and breadth of metabolic testing.
• Imaging, cell-counting, and digital analytical technologies are increasing in compact hematology and urinalysis. Automated image processing, flow-based measurement, machine vision, and algorithmic interpretation are progressively allowing sophisticated tests to move into smaller analyzer footprints.

 

By Sample Type

• Whole blood and capillary blood represent the largest sample category because they are used across blood gas, electrolyte, HbA1c, hematology, coagulation, glucose, cardiac marker, and other testing. Fingerstick collection is especially valuable in physician offices and chronic disease management, while arterial and venous samples dominate acute care.
• Respiratory swabs are a major high-growth category because they support influenza, RSV, SARS-CoV-2, Group A Streptococcus, and multiplex respiratory testing. Seasonal peaks can materially influence instrument utilization and cartridge demand.
• Urine is important for albumin-to-creatinine ratio, pregnancy testing, urinalysis, drugs of abuse, urinary tract infection assessment, and selected molecular applications. Integration of urine testing with metabolic disease management increases its strategic importance.
• Plasma and serum remain relevant for selected chemistry, immunoassay, and biomarker workflows, particularly in facilities that already perform basic specimen preparation.
• Other specimen types, including vaginal swabs, throat swabs, nasopharyngeal samples, stool-related samples, and selected lesion or specialty specimens, are becoming increasingly important as molecular menus broaden.

 

By End User

• Hospitals and integrated health systems account for the largest market share because they operate the most diverse POCT fleets. Benchtop analyzers may be deployed in emergency departments, ICUs, operating rooms, neonatal units, labor and delivery, satellite laboratories, infectious disease areas, oncology units, and outpatient departments. Enterprise contracting, connectivity, automated QC, cybersecurity, and standardized consumables strongly influence purchasing.
• Physician office laboratories and specialty clinics represent a significant expansion opportunity. Diabetes, nephrology, cardiology, infectious disease, pediatrics, family medicine, internal medicine, and women’s health practices can use rapid testing to complete the diagnostic and treatment loop during one visit.
• Urgent care and retail clinics are highly attractive for respiratory and infectious disease platforms. These sites prioritize rapid results, simple operation, predictable cartridge cost, small footprint, CLIA-waived workflows, and the ability to operate with limited laboratory staff.
• Ambulatory surgery centers and outpatient facilities represent a growing end-user category for selected blood gas, electrolyte, coagulation, chemistry, and perioperative tests. As more care shifts outside inpatient hospitals, compact analyzers that fit lower-volume economics should gain traction.
• Community health centers, public health settings, correctional facilities, substance-use treatment centers, and other decentralized care sites are becoming increasingly important for infectious disease testing. The FDA authorization of point-of-care hepatitis C RNA testing illustrates how benchtop molecular systems can support test-and-treat strategies in populations where conventional laboratory follow-up is difficult.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Benchtop Point-of-Care Testing Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs based on population growth, hospital and urgent-care density, chronic disease prevalence, laboratory access, rurality, health-system consolidation, academic medical center concentration, reimbursement mix, and adoption of decentralized diagnostics.

The South is estimated to represent the largest regional market at approximately USD 0.93 billion in 2025, followed by the West at USD 0.63 billion, the Northeast at USD 0.56 billion, and the Midwest at USD 0.46 billion. Under the forecast model, the West is expected to post the fastest percentage growth, while the South should retain the largest absolute revenue pool.

South

The South represents approximately 36% of the U.S. market in 2025 and is projected to approach USD 2.30 billion by 2035. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Delaware, West Virginia, Kentucky, Tennessee, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, and the District of Columbia under the broader report mapping.

Population growth is a major advantage. Texas exceeded 31.7 million residents in 2025, Florida exceeded 23.4 million, Georgia exceeded 11.3 million, and North Carolina approached 11.2 million. Texas recorded the largest numerical population increase between 2024 and 2025, followed by Florida and North Carolina. Expanding population bases support emergency care, primary care, urgent care, diabetes management, and infectious disease testing volumes.

Texas is the most strategically important Southern state for benchtop POCT. Houston, Dallas-Fort Worth, Austin, and San Antonio contain large integrated health systems, academic medical centers, specialty hospitals, physician networks, and rapidly growing outpatient infrastructures. High diabetes burden and large emergency-care volumes support HbA1c, metabolic, blood gas, and infectious disease analyzers.

Florida is especially attractive because of its large older-adult population and extensive outpatient care network. Diabetes, cardiovascular disease, chronic kidney disease, respiratory disease, and recurring healthcare utilization create demand for metabolic and acute-care POCT. The state also has a large hospital infrastructure and dense urgent-care presence.

North Carolina, Georgia, Tennessee, South Carolina, and Virginia should generate above-average placement opportunities through population growth and continued expansion of integrated delivery networks. South Carolina recorded one of the fastest percentage population increases in the country between 2024 and 2025, while North Carolina was among the fastest-growing states in absolute terms.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia present a different opportunity. Chronic disease burden is high, but rural access and laboratory staffing can be challenging. Small-footprint analyzers that allow community hospitals, clinics, and regional care centers to perform clinically important testing locally can therefore deliver disproportionate workflow value.

The South is forecast to expand at approximately 9.5% annually through 2035, supported by population growth, hospital investment, urgent-care expansion, chronic disease testing, decentralized molecular diagnostics, and a large pool of facilities seeking alternatives to central-laboratory turnaround.

West

The West represented approximately USD 0.63 billion in 2025 and is expected to reach nearly USD 1.65 billion by 2035, implying the fastest regional CAGR at approximately 10.1%. The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, Idaho, Montana, Wyoming, New Mexico, Alaska, and Hawaii.

California is the region’s anchor and remains the largest U.S. state by population at approximately 39.4 million residents in 2025. Its combination of major academic health systems, integrated delivery networks, technology-oriented providers, biotechnology clusters, public health infrastructure, and extensive outpatient care makes it a key launch environment for advanced POCT systems.

California buyers are particularly important for connectivity, digital workflow, antimicrobial stewardship, molecular diagnostics, and enterprise POCT governance. Health systems with geographically distributed outpatient networks can generate significant analyzer placement volumes under standardized purchasing arrangements.

Washington, Colorado, Oregon, and Utah have sophisticated health systems and strong adoption of digital health infrastructure. These markets are favorable for platforms that integrate with enterprise middleware, remote quality systems, and EHR workflows.

Arizona and Nevada combine rapid population growth with expanding older-adult populations, supporting diabetes, renal, respiratory, and acute-care testing. Arizona exceeded 7.6 million residents in 2025 and remained one of the country’s faster-growing states. Nevada’s expanding metropolitan markets create similar decentralized diagnostic demand.

Idaho and Utah are smaller but rapidly growing markets where new ambulatory capacity can create greenfield analyzer-placement opportunities. Montana, Wyoming, New Mexico, Alaska, and Hawaii have lower absolute testing volumes but present important decentralized-care use cases because distance from centralized laboratory infrastructure can magnify the value of rapid local testing.

Northeast

The Northeast represented approximately USD 0.56 billion in 2025 and is projected to reach approximately USD 1.31 billion by 2035. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Vermont, New Hampshire, and Maine.

The Northeast has a smaller population than the South but a particularly high concentration of academic medical centers, teaching hospitals, specialty care, laboratory expertise, and high-value healthcare utilization. This creates strong demand for premium molecular, critical-care, and connected POCT platforms.

New York, with approximately 20 million residents in 2025, is the region’s largest market. Major health systems in New York City and across the state operate complex multi-site networks where standardized POCT can help connect hospital and ambulatory care.

Pennsylvania and New Jersey add large population pools and strong hospital infrastructures. Pennsylvania exceeded 13 million residents in 2025, while New Jersey exceeded 9.5 million. These states are attractive for diabetes testing, emergency diagnostics, molecular infectious disease systems, and physician-office testing.

Massachusetts has a smaller population but disproportionate influence because of its concentration of academic medicine, biotechnology, clinical research, and technology evaluation. Manufacturers seeking clinical champions, evidence-generation partners, or early adoption sites frequently prioritize this market.

Connecticut, Rhode Island, New Hampshire, Vermont, and Maine are smaller markets. However, aging populations and rural areas in northern New England can support decentralized testing where specimen transportation delays are clinically inconvenient.

Growth in the Northeast is expected to remain strong but slightly below the South and West because the region has slower population expansion and comparatively mature healthcare infrastructure. Premium assay mix and early adoption should nevertheless sustain high revenue per installed analyzer.

Midwest

The Midwest accounted for approximately USD 0.46 billion in 2025 and is forecast to reach approximately USD 0.96 billion by 2035. The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois, Ohio, and Michigan are the largest state markets by population and healthcare utilization. Illinois had approximately 12.7 million residents in 2025, Ohio approximately 11.9 million, and Michigan more than 10.1 million. Chicago, Cleveland, Columbus, Detroit, Ann Arbor, Minneapolis-St. Paul, Indianapolis, Milwaukee, St. Louis, and other metropolitan markets support large hospital systems and sophisticated diagnostic programs.

Minnesota is strategically important because of its medtech ecosystem and concentration of high-quality integrated healthcare delivery. Wisconsin, Indiana, and Missouri provide substantial community-hospital and outpatient demand.

Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller populations but can benefit substantially from decentralized diagnostics because rural healthcare facilities frequently face specimen-transport and laboratory-staffing constraints. For these sites, a benchtop platform capable of running several high-value tests may be economically attractive even at lower overall utilization.

The Midwest is projected to grow more slowly than the other major regions, but it remains a durable market for blood gas, diabetes, hematology, coagulation, respiratory, and community-hospital POCT. Vendor service coverage, distributor support, instrument reliability, and consumable economics can be particularly important outside major metropolitan centers.

 

Key Market Players

The U.S. Benchtop Point-of-Care Testing Devices Competitive Landscape is moderately concentrated within individual technology categories but fragmented across the overall market. No single manufacturer controls molecular POCT, blood gas, diabetes testing, immunoassay, hematology, coagulation, and urinalysis simultaneously.

Key competitors include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Cepheid/Danaher, bioMérieux, QuidelOrtho, Werfen, Radiometer, Nova Biomedical, Sysmex America, QIAGEN, Thermo Fisher Scientific, ACON Laboratories, EKF Diagnostics, ARKRAY USA, Sekisui Diagnostics, HORIBA Medical, Sight Diagnostics, PixCell Medical, binx health, MeMed, Trinity Biotech, and Baebies.

Abbott has strategic strength through instrumented molecular and chronic disease testing, including ID NOW, Afinion, and Cholestech-related workflows. Roche is strongly positioned in rapid molecular testing through cobas Liat and has expanded its near-patient infectious disease menu. Siemens Healthineers has a durable position in diabetes and urine testing through platforms such as DCA Vantage and CLINITEK-related systems, as well as a broader hospital diagnostics footprint.

Cepheid is one of the most important competitors in compact molecular diagnostics because GeneXpert Xpress combines cartridge-based molecular testing with a two- or four-module benchtop configuration. bioMérieux has strengthened its decentralized molecular position with BIOFIRE SPOTFIRE syndromic testing. QuidelOrtho remains a major competitor in instrumented immunoassay and respiratory testing through Sofia 2 and related assays.

Werfen, Radiometer, and Nova Biomedical are major competitors in blood gas, electrolyte, and critical-care testing. Their differentiation increasingly depends on analytical menu, automated quality assurance, cartridge design, sample volume, uptime, data management, and fleet standardization.

Sysmex, Sight Diagnostics, PixCell Medical, and HORIBA participate in compact hematology and cell-analysis opportunities. ACON, ARKRAY, EKF, Sekisui, and Trinity Biotech compete across urinalysis, HbA1c, chemistry, immunodiagnostics, and specialty POC niches. binx health and MeMed illustrate the continuing emergence of specialized companies attempting to create new decentralized infectious disease workflows.

The most defensible competitive positions will come from high cartridge utilization rather than analyzer placements alone. Manufacturers that achieve menu expansion on an existing platform can increase revenue per installed system while lowering incremental commercial acquisition cost.

 

Recent Developments

Recent developments demonstrate that the U.S. benchtop POCT market is progressing from rapid screening toward increasingly sophisticated diagnostic decision-making.

In 2024, the FDA permitted marketing of the first point-of-care hepatitis C RNA test, Cepheid’s Xpert HCV test for use on GeneXpert Xpress. The test enables HCV RNA detection from fingerstick blood in appropriately certified point-of-care settings and can support a same-visit test-and-treat pathway. This is strategically important because it demonstrates that complex molecular confirmation historically associated with laboratory testing can move into decentralized care.

During 2024, CLIA-waiver activity also expanded across several instrumented categories. BIOFIRE SPOTFIRE Respiratory/Sore Throat testing received relevant waiver decisions, while the Nova Allegro HbA1c assay received a CLIA-waiver decision in November 2024. Such developments increase the range of sophisticated diagnostic tests that can be performed outside traditional moderate- and high-complexity laboratories.

In January 2025, Roche received FDA clearance and CLIA waiver for cobas Liat molecular STI panels. The tests provide rapid molecular detection of sexually transmitted infections in decentralized settings and illustrate the market’s movement beyond respiratory disease into higher-value same-visit molecular diagnostics.

Roche subsequently expanded the cobas Liat menu into Bordetella detection, including testing relevant to pertussis, further demonstrating the commercial importance of menu expansion on an established analyzer footprint.

In September 2026, FDA CLIA records reflected additional waived applications associated with QuidelOrtho’s Sofia 2 platform, including influenza A+B, RSV, Group A Streptococcus and selected other assays. The strategic significance is not limited to individual tests. A broader menu increases instrument utilization across multiple seasonal and routine clinical workflows and can improve the return on analyzer placement for customers and manufacturers.

The next competitive phase is likely to focus on consolidated syndromic menus, faster molecular turnaround, expanded STI and antimicrobial stewardship applications, simplified sample-to-answer processing, enterprise connectivity, AI-supported result interpretation, and more aggressive movement of testing into nontraditional care settings.

 

Conclusion

The U.S. Benchtop Point-of-Care Testing Devices Market Size & Share is positioned to expand from approximately USD 2.58 billion in 2025 to USD 6.22 billion by 2035, representing a CAGR of 9.20% during 2026–2035.

The market is being reshaped by an important change in how U.S. healthcare organizations value diagnostics. Central laboratories will continue to dominate high-volume testing, but clinical organizations increasingly recognize that laboratory efficiency and clinical workflow efficiency are not always the same. When a rapid result changes treatment, disposition, isolation, medication adjustment, or follow-up during the current encounter, near-patient testing can create economic value beyond the assay itself.

Molecular diagnostic analyzers are expected to represent the strongest premium growth opportunity as respiratory, STI, hepatitis, and other sophisticated tests move closer to patients. Blood gas and critical-care systems will remain a durable hospital-based revenue pool. HbA1c and renal testing will benefit from the exceptional scale of diabetes, prediabetes, and CKD in the United States. Instrumented immunoassay platforms will continue to serve high-volume urgent-care and respiratory workflows, while compact hematology, coagulation, urinalysis, and chemistry systems broaden the decentralized testing ecosystem.

The South should remain the largest geographic market, supported by Texas, Florida, Georgia, North Carolina, Tennessee, Virginia, and other rapidly expanding states. The West is expected to record the fastest growth due to technology adoption, outpatient expansion, population growth in several states, and demand for connected diagnostics. The Northeast will remain a premium early-adoption market, while the Midwest will offer stable hospital and rural-care demand.

For manufacturers, the strategic objective should not be maximizing instrument placements without regard to utilization. The more valuable model is to establish an analyzer footprint, expand the test menu, integrate the platform into clinical workflows, connect the installed fleet to enterprise information systems, and capture recurring cartridge volume.

For health systems and diagnostic buyers, the key purchasing questions will increasingly center on total workflow economics: how quickly results reach the clinician, how many patient encounters can be completed without send-out testing, whether the system can operate under the desired CLIA classification, how reliably decentralized operators can use it, whether QC can be centrally governed, how seamlessly results enter the medical record, and whether the platform can support additional assays over its useful life.

Companies able to combine analytical quality, operational simplicity, broad test menus, CLIA-accessible workflows, connectivity, reliable service, and defensible clinical economics are likely to capture the largest share of the U.S. benchtop point-of-care testing opportunity through 2035.

 

TABLE OF CONTENT

1. U.S. Benchtop Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Benchtop POCT Device Manufacturers
1.6.2. Assay, Cartridge, Reagent, Sensor and Component Suppliers
1.6.3. Hospitals and Integrated Delivery Networks
1.6.4. Physician Office Laboratories and Specialty Clinics
1.6.5. Urgent Care, Retail Clinic and Ambulatory Care Operators
1.6.6. Group Purchasing Organizations, Distributors and Diagnostic Channel Partners
1.6.7. Laboratory Directors, POCT Coordinators and Clinical Decision-Makers
1.6.8. Payers, FDA, CMS and CLIA Regulatory Stakeholders

What this section provides: This section establishes the market boundary, included benchtop analyzer categories, study scope, methodology, assumptions, and stakeholder ecosystem so clients understand how the U.S. Benchtop Point-of-Care Testing Devices Market is defined, measured, and validated.

2. U.S. Benchtop Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size Outlook, 2021–2035 (US$ Billion)
2.8. High-Growth Opportunity Areas
2.8.1. Rapid Molecular Point-of-Care Diagnostics
2.8.2. Multiplex Respiratory and Infectious Disease Testing
2.8.3. HbA1c and Cardiometabolic Testing
2.8.4. Connected Blood Gas and Critical-Care Testing
2.8.5. Decentralized Physician Office and Urgent Care Testing

What this section provides: This section provides decision-makers with a concise view of market size, historical performance, forecast growth, competitive intensity, technology direction, and the most commercially attractive benchtop POCT opportunities through 2035.

3. U.S. Benchtop Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Decentralization of Diagnostic Testing Across U.S. Care Settings
3.1.2. Rising Diabetes, CKD and Cardiometabolic Disease Testing Requirements
3.1.3. Sustained Respiratory and Infectious Disease Testing Demand
3.1.4. Expansion of CLIA-Waived Instrumented Testing
3.1.5. Need for Faster Clinical Decision-Making and Reduced Turnaround Time
3.1.6. Laboratory Workforce Constraints and Decentralized Testing Adoption
3.1.7. Expansion of Urgent Care and Physician Office Laboratory Infrastructure
3.2. Restraints and Their Impact Analysis
3.2.1. Analyzer Acquisition and Recurring Cartridge Costs
3.2.2. Decentralized Quality-Control and Operator Competency Requirements
3.2.3. Reimbursement Variability Across Point-of-Care Tests
3.2.4. Competition from Central Laboratories and Handheld Testing Platforms
3.2.5. Instrument Standardization and Vendor Lock-In Concerns
3.3. Opportunities and Their Impact Analysis
3.3.1. Rapid Molecular Assay Menu Expansion
3.3.2. Same-Visit STI, Hepatitis and Infectious Disease Testing
3.3.3. Enterprise-Connected POCT Fleets Across Integrated Health Systems
3.3.4. Rural and Community Healthcare Deployment
3.3.5. Multi-Assay and Multi-Disease Benchtop Platforms
3.3.6. Expansion of Decentralized Chronic Disease Screening
3.4. Challenges and Their Impact Analysis
3.4.1. Seasonal Variability in Respiratory Test Utilization
3.4.2. Cartridge and Reagent Supply-Chain Reliability
3.4.3. LIS/EHR Interoperability and Cybersecurity Requirements
3.4.4. Regulatory Compliance Across Distributed Testing Sites
3.4.5. Maintaining Analytical Quality Outside Core Laboratories
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Analyzer Installed-Base and Recurring Consumables Economics
3.8. Hospital and IDN Procurement Behavior Analysis
3.9. POCT Coordinator Workflow and Governance Analysis

What this section provides: This section evaluates the clinical, operational, economic, reimbursement, regulatory, and procurement forces shaping U.S. benchtop POCT demand and helps clients identify growth catalysts, adoption barriers, and execution risks.

4. U.S. Benchtop Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Analyzer and Test Consumable Pricing Trend Analysis, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Analyzer Placement, Reagent Rental and Recurring Revenue Models
4.6. Impact of Digitalization and Connected Point-of-Care Diagnostics
4.7. Application & Innovation Landscape
4.8. FDA Regulatory Framework Analysis
4.9. CLIA Waiver and Test Complexity Landscape
4.10. CMS Reimbursement and Coverage Landscape
4.11. CPT Coding and Test Payment Considerations
4.12. Import/Export Restrictions & Tariff Impact
4.13. Government Initiatives and Public Health Programs
4.14. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.15. Hospital Value Analysis Committee Decision Framework
4.16. Laboratory Standardization and POCT Governance Framework

What this section provides: This section gives clients an integrated understanding of regulation, CLIA classification, reimbursement, pricing, recurring-consumable economics, connectivity, supply chains, and procurement factors influencing the U.S. benchtop POCT industry.

5. U.S. Benchtop Point-of-Care Testing Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Molecular Diagnostic Analyzers
5.1.2.1. Rapid PCR Analyzers
5.1.2.2. Isothermal Nucleic Acid Amplification Analyzers
5.1.2.3. Multiplex/Syndromic Molecular Analyzers
5.1.2.4. Other Benchtop Molecular Platforms
5.1.3. Blood Gas, Electrolyte and Critical-Care Analyzers
5.1.3.1. Blood Gas Analyzers
5.1.3.2. Electrolyte Analyzers
5.1.3.3. Blood Gas/Electrolyte Combination Systems
5.1.3.4. Multi-Parameter Critical-Care Analyzers
5.1.4. HbA1c and Cardiometabolic Analyzers
5.1.4.1. HbA1c Analyzers
5.1.4.2. Lipid Testing Analyzers
5.1.4.3. Albumin and Creatinine Testing Systems
5.1.4.4. Multi-Parameter Cardiometabolic Platforms
5.1.5. Instrumented Immunoassay Analyzers
5.1.5.1. Infectious Disease Immunoassay Analyzers
5.1.5.2. Cardiac Biomarker Analyzers
5.1.5.3. Hormone and Pregnancy-Related Testing Systems
5.1.5.4. Other Instrumented Immunoassay Systems
5.1.6. Compact Hematology, Coagulation, Urinalysis and Chemistry Analyzers
5.1.6.1. Compact Hematology Analyzers
5.1.6.2. Coagulation Analyzers
5.1.6.3. Urinalysis Analyzers
5.1.6.4. Compact Clinical Chemistry Analyzers

What this section provides: This section identifies the benchtop analyzer categories generating the largest revenue pools and highlights product areas expected to gain share through rapid molecular testing, chronic disease management, critical-care diagnostics, and multi-assay platform adoption.

6. U.S. Benchtop Point-of-Care Testing Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Infectious Disease Testing
6.1.2.1. Influenza Testing
6.1.2.2. RSV Testing
6.1.2.3. SARS-CoV-2 Testing
6.1.2.4. Group A Streptococcus Testing
6.1.2.5. Sexually Transmitted Infection Testing
6.1.2.6. Hepatitis and Other Infectious Disease Testing
6.1.3. Diabetes and Renal Disease Management
6.1.3.1. HbA1c Testing
6.1.3.2. Albumin-to-Creatinine Ratio Testing
6.1.3.3. Creatinine and Renal Function Testing
6.1.3.4. Lipid and Cardiometabolic Testing
6.1.4. Critical-Care and Emergency Diagnostics
6.1.4.1. Blood Gas Analysis
6.1.4.2. Electrolyte Testing
6.1.4.3. Lactate and Metabolite Testing
6.1.4.4. Co-Oximetry and Multi-Parameter Critical-Care Testing
6.1.5. Cardiac and Coagulation Testing
6.1.5.1. Cardiac Biomarker Testing
6.1.5.2. Coagulation Testing
6.1.5.3. Anticoagulation Management
6.1.6. General Primary Care and Specialty Diagnostics
6.1.6.1. Hematology Testing
6.1.6.2. Urinalysis
6.1.6.3. Pregnancy and Reproductive Health Testing
6.1.6.4. General Chemistry Testing
6.1.6.5. Other Specialty Diagnostic Applications

What this section provides: This section evaluates demand by clinical use case and helps clients identify applications where rapid turnaround, same-visit treatment, disease burden, reimbursement, and decentralized testing create the strongest commercial opportunity.

7. U.S. Benchtop Point-of-Care Testing Devices Market – By Technology

7.1. Overview
7.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
7.1.2. Nucleic Acid Amplification Technologies
7.1.2.1. PCR-Based Platforms
7.1.2.2. Isothermal Amplification Platforms
7.1.2.3. Multiplex Molecular Detection
7.1.3. Fluorescent and Optical Immunoassay Technologies
7.1.3.1. Fluorescence Immunoassay
7.1.3.2. Optical Reflectance and Reader-Based Immunoassay
7.1.3.3. Chemiluminescent and Related Detection Methods
7.1.4. Electrochemical and Biosensor-Based Technologies
7.1.4.1. Electrochemical Sensor Systems
7.1.4.2. Ion-Selective Electrode Technologies
7.1.4.3. Biosensor-Based Multi-Analyte Detection
7.1.5. Clinical Chemistry and Affinity-Based Technologies
7.1.5.1. Enzymatic Chemistry
7.1.5.2. Immunoturbidimetric and Affinity-Based Methods
7.1.5.3. Dry Chemistry and Cartridge-Based Chemistry
7.1.6. Imaging, Cell-Counting and Digital Analytical Technologies
7.1.6.1. Digital Cell Imaging
7.1.6.2. Flow-Based Cell Analysis
7.1.6.3. Machine Vision and Algorithm-Assisted Interpretation

What this section provides: This section assesses the analytical technologies supporting the next generation of U.S. benchtop POCT platforms and shows where molecular amplification, biosensors, optical detection, digital imaging, and automated analytical methods are changing competitive positioning.

8. U.S. Benchtop Point-of-Care Testing Devices Market – By Sample Type

8.1. Overview
8.1.1. Segment Share Analysis, By Sample Type, 2025 & 2035 (%)
8.1.2. Whole Blood and Capillary Blood
8.1.2.1. Fingerstick/Capillary Blood
8.1.2.2. Venous Whole Blood
8.1.2.3. Arterial Blood
8.1.3. Respiratory Swabs and Respiratory Specimens
8.1.3.1. Nasal Swabs
8.1.3.2. Nasopharyngeal Swabs
8.1.3.3. Throat Swabs
8.1.4. Urine
8.1.4.1. Routine Urine Specimens
8.1.4.2. Urine for Albumin/Creatinine Testing
8.1.4.3. Urine for Infectious Disease and Specialty Testing
8.1.5. Plasma and Serum
8.1.5.1. Plasma Specimens
8.1.5.2. Serum Specimens
8.1.6. Other Specimen Types
8.1.6.1. Vaginal and Genital Swabs
8.1.6.2. Stool-Related Specimens
8.1.6.3. Other Specialty Specimens

What this section provides: This section shows how specimen requirements influence clinical workflow, analyzer selection, patient accessibility, test turnaround, and the addressable utilization potential of different benchtop POCT platforms.

9. U.S. Benchtop Point-of-Care Testing Devices Market – By End User

9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
9.1.2. Hospitals and Integrated Health Systems
9.1.2.1. Emergency Departments
9.1.2.2. Intensive Care Units
9.1.2.3. Operating Rooms and Perioperative Units
9.1.2.4. Hospital Satellite Laboratories
9.1.2.5. Hospital Outpatient Departments
9.1.3. Physician Office Laboratories and Specialty Clinics
9.1.3.1. Primary Care and Internal Medicine Practices
9.1.3.2. Diabetes and Endocrinology Clinics
9.1.3.3. Nephrology and Cardiology Practices
9.1.3.4. Pediatric and Women’s Health Practices
9.1.4. Urgent Care and Retail Clinics
9.1.4.1. Independent Urgent Care Centers
9.1.4.2. Health-System-Owned Urgent Care Centers
9.1.4.3. Retail and Pharmacy-Based Clinics
9.1.5. Ambulatory Surgery Centers and Outpatient Facilities
9.1.5.1. Ambulatory Surgery Centers
9.1.5.2. Freestanding Outpatient Centers
9.1.5.3. Specialty Procedure Centers
9.1.6. Community, Public Health and Other Decentralized Care Settings
9.1.6.1. Federally Qualified and Community Health Centers
9.1.6.2. Public Health and Sexual Health Clinics
9.1.6.3. Correctional and Institutional Healthcare Settings
9.1.6.4. Rural and Critical Access Facilities
9.1.6.5. Other Decentralized Diagnostic Sites

What this section provides: This section identifies the healthcare settings generating analyzer placements and recurring test consumption and explains how purchasing criteria differ across hospitals, physician offices, urgent care, ambulatory facilities, and decentralized community settings.

10. U.S. Benchtop Point-of-Care Testing Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Installed-Base and Testing Volume Analysis
10.1.4. Regional Hospital, Physician Office and Urgent Care Infrastructure Analysis
10.1.5. Regional CLIA Laboratory and POCT Adoption Analysis
10.1.6. Regional Reimbursement and Procurement Dynamics

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Benchtop POCT Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Benchtop POCT Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Benchtop POCT Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.4.24. Delaware

10.4.24.1. Overview
10.4.24.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.24.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.24.4. Delaware Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.24.5. Delaware Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.24.6. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Benchtop POCT Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level intelligence across all 50 U.S. states, allowing clients to compare market size, diagnostic infrastructure, POCT adoption, analyzer demand, assay utilization, healthcare delivery characteristics, and state-level commercial opportunities.

11. U.S. Benchtop Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking by Analyzer Installed Base
11.3. Competitive Benchmarking by Assay Menu Breadth
11.4. Company Positioning Matrix
11.4.1. Leaders
11.4.2. Challengers
11.4.3. Innovators
11.4.4. Emerging Players
11.5. Competitive Strategy Analysis
11.5.1. Analyzer Placement Strategy
11.5.2. Reagent Rental and Consumables Strategy
11.5.3. CLIA-Waiver Strategy
11.5.4. Menu Expansion Strategy
11.5.5. IDN and Enterprise Contracting Strategy
11.6. Company Profiles

11.6.1. Abbott Laboratories
11.6.2. Roche Diagnostics
11.6.3. Siemens Healthineers
11.6.4. Cepheid (Danaher Corporation)
11.6.5. bioMérieux
11.6.6. QuidelOrtho Corporation
11.6.7. Radiometer Medical (Danaher Corporation)
11.6.8. Werfen
11.6.9. Nova Biomedical
11.6.10. Sysmex America
11.6.11. QIAGEN
11.6.12. Thermo Fisher Scientific
11.6.13. ARKRAY USA
11.6.14. EKF Diagnostics
11.6.15. Sekisui Diagnostics
11.6.16. HORIBA Medical
11.6.17. Sight Diagnostics
11.6.18. PixCell Medical
11.6.19. binx health
11.6.20. MeMed
11.6.21. Trinity Biotech
11.6.22. Baebies
11.6.23. ACON Laboratories
11.6.24. Randox Laboratories

11.7. Company Profile Assessment Framework
11.7.1. Company Overview
11.7.2. U.S. Benchtop POCT Product Portfolio
11.7.3. Key Analyzer Platforms and Assay Menu
11.7.4. U.S. Market Strategy
11.7.5. Financial and Commercial Positioning
11.7.6. FDA Clearance and CLIA-Waiver Positioning
11.7.7. Product Pipeline and Innovation Strategy
11.7.8. Partnerships, Distribution and Health-System Contracts
11.7.9. Recent Developments

What this section provides: This section gives clients competitor benchmarking, market-share visibility, analyzer and assay-menu positioning, installed-base strategy, regulatory differentiation, partnership activity, and strategic intelligence on leading U.S. benchtop POCT manufacturers.

12. U.S. Benchtop Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Rapid Sample-to-Answer Molecular Diagnostics
12.2.2. Multiplex and Syndromic Testing Platforms
12.2.3. Automated Cartridge and Microfluidic Technologies
12.2.4. AI-Assisted Result Interpretation
12.2.5. Enterprise POCT Connectivity and Remote Quality Management
12.2.6. Multi-Analyte and Multi-Disease Benchtop Platforms
12.3. Future CLIA-Waived Testing Landscape
12.4. Emerging Business Trends
12.4.1. Reagent Rental and Analyzer Placement Models
12.4.2. Assay Menu Expansion on Existing Installed Bases
12.4.3. IDN-Wide POCT Standardization
12.4.4. Decentralized Molecular Diagnostics Expansion
12.4.5. Shift Toward Same-Visit Diagnosis and Treatment
12.5. Business Opportunities for Startups and Existing Players
12.6. Investment Prioritization Matrix
12.7. High-Growth Product/Application Opportunity Matrix
12.8. Market White-Space Analysis

What this section provides: This section prepares clients for future diagnostic technology shifts, CLIA-waiver expansion, platform consolidation, assay-menu evolution, decentralized testing models, investment opportunities, and alternative market-growth scenarios through 2035.

13. U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations

13.1. Recommendations for Benchtop POCT Device Manufacturers
13.2. Recommendations for Assay and Consumables Manufacturers
13.3. Recommendations for Hospitals and Integrated Health Systems
13.4. Recommendations for Physician Office Laboratories and Urgent Care Operators
13.5. Recommendations for Investors and Private Equity Firms
13.6. Recommendations for Distributors and Channel Partners
13.7. Recommendations for New Entrants and Diagnostic Startups
13.8. Go-to-Market Strategy Considerations
13.9. Analyzer Placement and Installed-Base Expansion Strategy
13.10. Assay Menu and Recurring Revenue Expansion Guidance
13.11. Product Positioning and Portfolio Expansion Guidance
13.12. CLIA-Waiver and Regulatory Commercialization Strategy
13.13. State and Regional Market Prioritization Strategy

What this section provides: This section translates market intelligence into actionable strategies for analyzer placement, assay-menu expansion, recurring consumables revenue, health-system contracting, regulatory planning, channel expansion, investment decisions, and competitive differentiation.

14. U.S. Benchtop Point-of-Care Testing Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition and Product Inclusion Limitation
14.3. Data Use Limitation
14.4. Forecasting Limitation
14.5. State-Level Market Estimation Limitation
14.6. Legal Disclaimer
14.7. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s market-definition boundaries, state-level modeling limitations, forecasting assumptions, data-use conditions, third-party data considerations, and legal limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Benchtop Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Benchtop Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Benchtop Point-of-Care Testing Devices Market: Primary Research Framework
TABLE 5: U.S. Benchtop Point-of-Care Testing Devices Market: Secondary Research Framework
TABLE 6: U.S. Benchtop Point-of-Care Testing Devices Market: Data Validation and Forecasting Methodology
TABLE 7: U.S. Benchtop Point-of-Care Testing Devices Market: Key Assumptions
TABLE 8: U.S. Benchtop Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 9: U.S. Benchtop Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 10: U.S. Benchtop Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 11: U.S. Benchtop Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 12: U.S. Benchtop Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 13: U.S. Benchtop Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 14: U.S. Benchtop Point-of-Care Testing Devices Market: Base Year Market Positioning, 2025
TABLE 15: U.S. Benchtop Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 16: U.S. Benchtop Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 17: U.S. Benchtop Point-of-Care Testing Devices Market: High-Growth Opportunity Areas
TABLE 18: U.S. Benchtop Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 19: U.S. Benchtop Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 20: U.S. Benchtop Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 21: U.S. Benchtop Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 22: U.S. Benchtop Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 23: U.S. Benchtop Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 24: U.S. Benchtop Point-of-Care Testing Devices Market: Analyzer Installed-Base and Recurring Consumables Economics
TABLE 25: U.S. Benchtop Point-of-Care Testing Devices Market: Hospital and IDN Procurement Behavior Matrix
TABLE 26: U.S. Benchtop Point-of-Care Testing Devices Market: POCT Coordinator Workflow and Governance Matrix
TABLE 27: U.S. Benchtop Point-of-Care Testing Devices Market: Decentralized Diagnostic Adoption Factors
TABLE 28: U.S. Benchtop Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 29: U.S. Benchtop Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 30: U.S. Benchtop Point-of-Care Testing Devices Market: Analyzer Pricing Trends, 2025–2035
TABLE 31: U.S. Benchtop Point-of-Care Testing Devices Market: Cartridge and Consumables Pricing Trends, 2025–2035
TABLE 32: U.S. Benchtop Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 33: U.S. Benchtop Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 34: U.S. Benchtop Point-of-Care Testing Devices Market: Analyzer Placement and Reagent Rental Models
TABLE 35: U.S. Benchtop Point-of-Care Testing Devices Market: Connected POCT and Digitalization Impact
TABLE 36: U.S. Benchtop Point-of-Care Testing Devices Market: Application & Innovation Landscape
TABLE 37: U.S. Benchtop Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 38: U.S. Benchtop Point-of-Care Testing Devices Market: CLIA Waiver and Test Complexity Landscape
TABLE 39: U.S. Benchtop Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 40: U.S. Benchtop Point-of-Care Testing Devices Market: CPT Coding and Test Payment Considerations
TABLE 41: U.S. Benchtop Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 42: U.S. Benchtop Point-of-Care Testing Devices Market: Government Initiatives and Public Health Programs
TABLE 43: U.S. Benchtop Point-of-Care Testing Devices Market: Geopolitical and Supply-Chain Risk Analysis
TABLE 44: U.S. Benchtop Point-of-Care Testing Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 45: U.S. Benchtop Point-of-Care Testing Devices Market: Laboratory Standardization and POCT Governance Framework
TABLE 46: U.S. Benchtop Point-of-Care Testing Devices Market: Product Category Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Product Category
TABLE 48: U.S. Benchtop Point-of-Care Testing Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 49: U.S. Benchtop Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 50: Molecular Diagnostic Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Rapid PCR Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Multiplex and Syndromic Molecular Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Blood Gas, Electrolyte and Critical-Care Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: HbA1c and Cardiometabolic Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: Instrumented Immunoassay Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Compact Hematology Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Coagulation, Urinalysis and Compact Chemistry Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Benchtop Point-of-Care Testing Devices Market: Application Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by Application
TABLE 60: U.S. Benchtop Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 61: U.S. Benchtop Point-of-Care Testing Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 62: Infectious Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Respiratory Infectious Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: STI, Hepatitis and Other Molecular Infectious Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: Diabetes and Renal Disease Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: HbA1c Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: Renal and Cardiometabolic Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: Critical-Care and Emergency Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Cardiac and Coagulation Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: General Primary Care and Specialty Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Benchtop Point-of-Care Testing Devices Market: Technology Snapshot, 2025
TABLE 72: Segment Dashboard; Definition and Scope, by Technology
TABLE 73: U.S. Benchtop Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 74: U.S. Benchtop Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 75: Nucleic Acid Amplification Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: PCR-Based Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: Isothermal and Alternative Molecular Amplification Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Fluorescent and Optical Immunoassay Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: Electrochemical and Biosensor-Based Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: Clinical Chemistry and Affinity-Based Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: Imaging, Cell-Counting and Digital Analytical Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Benchtop Point-of-Care Testing Devices Market: Sample Type Snapshot, 2025
TABLE 83: Segment Dashboard; Definition and Scope, by Sample Type
TABLE 84: U.S. Benchtop Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 85: U.S. Benchtop Point-of-Care Testing Devices Market: Segment Share Analysis, by Sample Type, 2025 & 2035 (%)
TABLE 86: Whole Blood and Capillary Blood Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: Arterial and Venous Whole Blood Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: Respiratory Swabs and Respiratory Specimens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: Urine Specimen Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Plasma and Serum Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: Other Specialty Specimen Types Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: U.S. Benchtop Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 93: Segment Dashboard; Definition and Scope, by End User
TABLE 94: U.S. Benchtop Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 95: U.S. Benchtop Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 96: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Emergency Department and Critical-Care POCT Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Physician Office Laboratories and Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Urgent Care and Retail Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Ambulatory Surgery Centers and Outpatient Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Community, Public Health and Other Decentralized Care Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: U.S. Benchtop Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 103: Segment Dashboard; Definition and Scope, by Region
TABLE 104: U.S. Benchtop Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 105: U.S. Benchtop Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 106: U.S. Benchtop Point-of-Care Testing Devices Market: Regional Installed-Base and Testing Volume Analysis
TABLE 107: U.S. Benchtop Point-of-Care Testing Devices Market: Regional Hospital, POL and Urgent Care Infrastructure Analysis
TABLE 108: U.S. Benchtop Point-of-Care Testing Devices Market: Regional CLIA and Reimbursement Dynamics
TABLE 109: West Region U.S. Benchtop Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 110: West Region U.S. Benchtop Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 111: West Region U.S. Benchtop Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: West Region U.S. Benchtop Point-of-Care Testing Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 113: West Region U.S. Benchtop Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 114: West Region U.S. Benchtop Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 115: West Region U.S. Benchtop Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 116: West Region U.S. Benchtop Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 117: California Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Washington Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Arizona Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Colorado Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Oregon Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Utah Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Nevada Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: New Mexico Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Idaho Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Montana Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Wyoming Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Alaska Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Hawaii Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 131: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 132: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 133: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 134: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 135: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 136: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 137: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 138: New York Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Massachusetts Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: New Jersey Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Pennsylvania Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Connecticut Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Maine Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Vermont Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: New Hampshire Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Rhode Island Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: South Region U.S. Benchtop Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 148: South Region U.S. Benchtop Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 149: South Region U.S. Benchtop Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 150: South Region U.S. Benchtop Point-of-Care Testing Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 151: South Region U.S. Benchtop Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 152: South Region U.S. Benchtop Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 153: South Region U.S. Benchtop Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 154: South Region U.S. Benchtop Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 155: Texas Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Florida Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Georgia Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: North Carolina Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Tennessee Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: South Carolina Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Alabama Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Mississippi Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Louisiana Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Arkansas Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Kentucky Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Oklahoma Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Virginia Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Maryland Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: West Virginia Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Delaware Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 172: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 173: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 174: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 175: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 176: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 177: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 178: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 179: Illinois Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 180: Ohio Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 181: Michigan Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 182: Minnesota Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 183: Indiana Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 184: Wisconsin Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 185: Missouri Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 186: Iowa Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 187: Kansas Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 188: Nebraska Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 189: North Dakota Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 190: South Dakota Benchtop Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 191: U.S. Benchtop Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 192: U.S. Benchtop Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 193: U.S. Benchtop Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 194: U.S. Benchtop Point-of-Care Testing Devices Market: Analyzer Installed-Base Benchmarking
TABLE 195: U.S. Benchtop Point-of-Care Testing Devices Market: Assay Menu Breadth Benchmarking
TABLE 196: U.S. Benchtop Point-of-Care Testing Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 197: U.S. Benchtop Point-of-Care Testing Devices Market: CLIA-Waived Portfolio Benchmarking
TABLE 198: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 199: Abbott Laboratories: Company Profile
TABLE 200: Roche Diagnostics: Company Profile
TABLE 201: Siemens Healthineers: Company Profile
TABLE 202: Cepheid (Danaher Corporation): Company Profile
TABLE 203: bioMérieux: Company Profile
TABLE 204: QuidelOrtho Corporation: Company Profile
TABLE 205: Radiometer Medical (Danaher Corporation): Company Profile
TABLE 206: Werfen: Company Profile
TABLE 207: Nova Biomedical: Company Profile
TABLE 208: Sysmex America: Company Profile
TABLE 209: QIAGEN: Company Profile
TABLE 210: Thermo Fisher Scientific: Company Profile
TABLE 211: ARKRAY USA: Company Profile
TABLE 212: EKF Diagnostics: Company Profile
TABLE 213: Sekisui Diagnostics: Company Profile
TABLE 214: HORIBA Medical: Company Profile
TABLE 215: Sight Diagnostics: Company Profile
TABLE 216: PixCell Medical: Company Profile
TABLE 217: binx health: Company Profile
TABLE 218: MeMed: Company Profile
TABLE 219: Trinity Biotech: Company Profile
TABLE 220: Baebies: Company Profile
TABLE 221: ACON Laboratories: Company Profile
TABLE 222: Randox Laboratories: Company Profile
TABLE 223: U.S. Benchtop Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 224: U.S. Benchtop Point-of-Care Testing Devices Market: Optimistic, Realistic and Pessimistic Scenario Comparison
TABLE 225: U.S. Benchtop Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 226: U.S. Benchtop Point-of-Care Testing Devices Market: Future CLIA-Waived Testing Landscape
TABLE 227: U.S. Benchtop Point-of-Care Testing Devices Market: Rapid Molecular Diagnostics Opportunity Matrix
TABLE 228: U.S. Benchtop Point-of-Care Testing Devices Market: Enterprise Connectivity and Remote Quality Management Opportunity Matrix
TABLE 229: U.S. Benchtop Point-of-Care Testing Devices Market: Emerging Business Trends
TABLE 230: U.S. Benchtop Point-of-Care Testing Devices Market: Business Opportunities for Startups and Existing Players
TABLE 231: U.S. Benchtop Point-of-Care Testing Devices Market: High-Growth Product/Application Opportunity Matrix
TABLE 232: U.S. Benchtop Point-of-Care Testing Devices Market: Market White-Space Analysis
TABLE 233: U.S. Benchtop Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 234: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 235: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations for Assay and Consumables Manufacturers
TABLE 236: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 237: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations for Physician Office and Urgent Care Operators
TABLE 238: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 239: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 240: U.S. Benchtop Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 241: U.S. Benchtop Point-of-Care Testing Devices Market: Go-to-Market Strategy Considerations
TABLE 242: U.S. Benchtop Point-of-Care Testing Devices Market: Analyzer Placement and Installed-Base Expansion Strategy
TABLE 243: U.S. Benchtop Point-of-Care Testing Devices Market: Assay Menu and Recurring Revenue Expansion Guidance
TABLE 244: U.S. Benchtop Point-of-Care Testing Devices Market: CLIA-Waiver and Regulatory Commercialization Strategy
TABLE 245: U.S. Benchtop Point-of-Care Testing Devices Market: State and Regional Prioritization Matrix
TABLE 246: U.S. Benchtop Point-of-Care Testing Devices Market: Scope Limitation
TABLE 247: U.S. Benchtop Point-of-Care Testing Devices Market: Market Definition and Product Inclusion Limitation
TABLE 248: U.S. Benchtop Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 249: U.S. Benchtop Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 250: U.S. Benchtop Point-of-Care Testing Devices Market: State-Level Market Estimation Limitation
TABLE 251: U.S. Benchtop Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 252: U.S. Benchtop Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Benchtop Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Primary and Secondary Research Framework
FIGURE 4: Market Ecosystem Framework
FIGURE 5: Stakeholder Ecosystem
FIGURE 6: Market Attractiveness Analysis
FIGURE 7: U.S. Benchtop Point-of-Care Testing Devices Market Dynamics
FIGURE 8: PESTEL Analysis
FIGURE 9: Porter’s Five Forces Analysis
FIGURE 10: Value Chain Analysis
FIGURE 11: Supply Chain Analysis
FIGURE 12: Innovation & Patent Landscape, 2021–2025
FIGURE 13: Clinical Workflow Economics Framework
FIGURE 14: Hospital and IDN Procurement Decision Framework
FIGURE 15: Analyzer Installed-Base and Recurring Consumables Revenue Model
FIGURE 16: POCT Governance and Quality Management Framework
FIGURE 17: U.S. Benchtop Point-of-Care Testing Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 18: U.S. Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 19: U.S. Benchtop Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 20: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 21: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Molecular Diagnostic Analyzers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Rapid PCR and Multiplex Molecular Analyzer Growth Comparison, 2021–2035
FIGURE 24: Blood Gas, Electrolyte and Critical-Care Analyzers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 25: HbA1c and Cardiometabolic Analyzers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 26: Instrumented Immunoassay Analyzers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 27: Compact Hematology, Coagulation, Urinalysis and Chemistry Analyzer Opportunity Analysis
FIGURE 28: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 29: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Infectious Disease Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 31: Respiratory Testing Opportunity Analysis, 2025–2035
FIGURE 32: STI and Hepatitis Point-of-Care Molecular Testing Opportunity Analysis
FIGURE 33: Diabetes and Renal Disease Management Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 34: Critical-Care and Emergency Diagnostics Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 35: Cardiac and Coagulation Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 36: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 37: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Nucleic Acid Amplification Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: PCR and Isothermal Amplification Technology Comparison
FIGURE 40: Fluorescent and Optical Immunoassay Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 41: Electrochemical and Biosensor-Based Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 42: Imaging, Cell-Counting and Digital Analytical Technology Opportunity Map
FIGURE 43: Sample Type Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Sample Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Whole Blood and Capillary Blood Testing Market Growth Analysis
FIGURE 46: Respiratory Specimen Testing Market Growth Analysis
FIGURE 47: Urine, Plasma, Serum and Other Specialty Specimen Opportunity Analysis
FIGURE 48: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 49: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 51: Physician Office Laboratories and Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 52: Urgent Care and Retail Clinics Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 53: Ambulatory and Decentralized Care Settings Opportunity Analysis
FIGURE 54: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 55: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: U.S. Regional POCT Installed-Base and Testing Volume Comparison
FIGURE 57: Regional CLIA, Hospital and Urgent Care Infrastructure Comparison
FIGURE 58: West Region U.S. Benchtop Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 59: West Region Market Share Analysis by State, 2025
FIGURE 60: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: California Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 62: Washington Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 63: Arizona Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 64: Colorado Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: Oregon Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Utah Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: Nevada Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: New Mexico Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: Idaho Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Montana Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: Wyoming Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Alaska Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: Hawaii Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Northeast Region U.S. Benchtop Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 75: Northeast Region Market Share Analysis by State, 2025
FIGURE 76: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: New York Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 78: Massachusetts Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: New Jersey Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 80: Pennsylvania Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 81: Connecticut Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 82: Maine Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Vermont Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: New Hampshire Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 85: Rhode Island Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: South Region U.S. Benchtop Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 87: South Region Market Share Analysis by State, 2025
FIGURE 88: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Texas Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 90: Florida Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 91: Georgia Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 92: North Carolina Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: Tennessee Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: South Carolina Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: Alabama Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: Mississippi Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: Louisiana Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Arkansas Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: Kentucky Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: Oklahoma Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Virginia Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Maryland Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: West Virginia Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: Delaware Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Midwest Region U.S. Benchtop Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 106: Midwest Region Market Share Analysis by State, 2025
FIGURE 107: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Illinois Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 109: Ohio Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: Michigan Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: Minnesota Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: Indiana Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 113: Wisconsin Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 114: Missouri Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 115: Iowa Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 116: Kansas Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 117: Nebraska Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 118: North Dakota Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 119: South Dakota Benchtop Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 120: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 121: Company Positioning Matrix
FIGURE 122: Analyzer Installed-Base Benchmarking
FIGURE 123: Assay Menu Breadth Benchmarking
FIGURE 124: CLIA-Waived Product Portfolio Benchmarking
FIGURE 125: Key Player Product Portfolio Benchmarking
FIGURE 126: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 127: U.S. Benchtop POCT Innovation Roadmap
FIGURE 128: Rapid Molecular Diagnostics Adoption Roadmap
FIGURE 129: Multiplex and Syndromic Testing Opportunity Map
FIGURE 130: CLIA-Waived Testing Expansion Roadmap
FIGURE 131: Connected POCT and Enterprise Integration Roadmap
FIGURE 132: Analyzer-to-Consumables Recurring Revenue Expansion Framework
FIGURE 133: Future Market Scenario Analysis, 2026–2035
FIGURE 134: Optimistic, Realistic and Pessimistic Forecast Scenario Comparison
FIGURE 135: Disruptive Technologies Impact Matrix
FIGURE 136: Emerging Business Trends Matrix
FIGURE 137: High-Growth Product/Application Opportunity Map
FIGURE 138: Market White-Space Opportunity Map
FIGURE 139: Investment Prioritization Matrix
FIGURE 140: Strategic Growth Roadmap for U.S. Benchtop POCT Companies
FIGURE 141: Go-to-Market Strategy Framework
FIGURE 142: Analyzer Placement and Installed-Base Expansion Framework
FIGURE 143: Assay Menu and Recurring Revenue Expansion Framework
FIGURE 144: CLIA-Waiver and Regulatory Commercialization Framework
FIGURE 145: State and Regional Market Prioritization Framework
FIGURE 146: Product Positioning and Portfolio Expansion Framework
FIGURE 147: Report Scope and Disclaimer Framework